Topoizomeraz İnhibitörlerinin Etki Mekanizmaları ve Sınıflandırılması
Özet
DNA topoizomerazları, replikasyon ve transkripsiyon gibi temel hücresel süreçlerde DNA'nın süper sarılmasını düzenleyen nükleer enzimlerdir. Bu enzimler, DNA zincirlerini kırıp yeniden birleştirme mekanizmalarına göre Tip-1 (ATP'den bağımsız) ve Tip-2 (ATP'ye bağımlı) olmak üzere iki ana sınıfa ayrılır. Kanser tedavisinde kritik birer moleküler hedef olan topoizomeraz inhibitörleri, bu enzimlerin işlevlerini bozarak hücreyi apoptoz veya nekroza götürür. Topoizomeraz-1 inhibitörleri arasında suda çözünürlüğü artırılmış kamptotesin analogları olan topotekan ve renal/biliyer yollarla atılan irinotekan öne çıkar. Topoizomeraz-2 inhibitörleri ise epipodofilotoksinler (etoposid, teniposid), akridinler (amsakrin) ve interkalasyon ile oksidatif stres yaratan antrasiklin türevlerini (doksorubisin, daunorubisin) kapsar. Antrasiklinlerin kardiyotoksik etkilerini azaltmak amacıyla mitoksantron gibi antrasendion türevleri geliştirilmiştir. Son olarak, topoizomeraz-2 katalitik inhibitörleri (merbaron, deksrazoksan, novobiosin) DNA hasarı oluşturmadan enzimin katalitik fonksiyonunu doğrudan engelleyerek sitotoksik etki gösterirler. Bu inhibitör ajanlar, modern onkolojik kemoterapinin temel yapı taşlarını oluşturmaktadır.
DNA topoisomerases are vital nuclear enzymes that regulate DNA supercoiling and topological states during fundamental cellular processes such as replication and transcription. Based on their mechanisms of cleaving and resealing DNA strands, they are classified into Type-1 (ATP-independent) and Type-2 (ATP-dependent) enzymes. As critical molecular targets in cancer therapy, topoisomerase inhibitors disrupt these enzymatic functions, leading to cell death via apoptosis or necrosis. Topoisomerase-1 inhibitors mainly include camptothecin analogs like topotecan and irinotecan, which exhibit distinct elimination pathways. Topoisomerase-2 inhibitors comprise epipodophyllotoxins (etoposide, teniposide), acridines (amsacrine), and anthracyclines (doxorubicin, daunorubicin) that induce DNA breaks and oxidative stress. To mitigate the characteristic cardiotoxicity associated with anthracyclines, anthracenedione derivatives like mitoxantrone have been developed. Additionally, catalytic topoisomerase-2 inhibitors, including merbarone, dexrazoxane, and novobiocin, exert cytotoxic effects by directly blocking the catalytic function without inducing direct DNA strand damage. Collectively, these inhibitory agents represent cornerstone components of modern oncological chemotherapy regimens.
Referanslar
Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem. 1996, 65-635.
Chen, A.Y. and Liu, L.F. 1994. DNA Topoisomerases: Essential Enzymes and Lethal Targets, Annu. Rev. Pharmacol. Toxicol., 34, 191-218.
Gupta M, Fujimori A,Pommier Y. Eukaryotic DNA topoisomerases I. Biochim Biophys Acta 1995;1262:1.
Bereger JM. Structure of DNA topoisomerases. Biochim Biophys Acta 1998;1400:3
Takano H, Kohno K, Matsuo K, Matsuda T, Kuwano M. DNA topoisomerase-targeting antitumor agents and drug resistance. Anticancer Drugs 1992;3-323.
Burden DA, Osherhoff N. Mecanism of of eukaryotictopoisomerases II and drugs targetedto the enzyme. Biochim Biophys Acta 1998;1400:139.
Wigley DB. Structure and mecanism of DNA topoisomerases. Annu. Rev. Biopkys Biomol Struct 1995;24-185.
Pantazis, P., Chatterjee, D., Han, Z., Wyche, J. 1999. Differentiation of human malignant melanoma cells that escape apoptosis following treatment with 9-nitrocamptothecin, Neoplasia, 1, 231.
Zamboni WC,Crom WR,Houghton PJ,Thompson JC,Stewart CF. Plasma protein binding of SN-38: the active metaboliteof irinotecan. Pharmacoterapy 1996;16-500.
Rowinsky EK, Grochow LB, Hendricks CB, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitör. J Clin Oncol 1992;10-647.
Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comperation of topoisomerase I inhition; Dna damage, cytotoxicity of camptothecinderivatives presently in clinical trials. J Natl Cancer İnst 1994;86-836.
lyer L, King CD, Mniitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11): role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1999,101-847.
Minami H, Ratain MJ, Ano Y, Shimokata K. Pharmacodynamic modeling of prolonged administration of etoposide. Cancer Chemother Pharmacol 1996, 39, 61-66.
8: Pui CH, Riberiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphocytic leukemia. N Engl J Med 1991, 325, 1682-1687.
Gormley P. E., Sethi V. S. & Cysyk R. L. (1978) Interaction of 4'-(9-acridinylamino)methanesulfon-m-anisidide with DNA and inhibition of oncornavirus reverse transcriptase and cellular nucleic acid polymerases. Cancer Res. 38, 1300.
3. Wang, J. C. Ann. Rev. Biochem. 1996, 65-635
Aligiannis, N.; Pouli, N.; Marakos, P.; Skaltsounis, A. L.; Florent, J. C.; Perchellet, E. M.; Sperfslage, B. J.; McIlvain, C. J.; Perchellet, J. P. J. Antibiot. 2002, 55, 181–190
DiMarco A, Zunino F. Casazza AM. Comparison of biochemical and biological methods in the evaluation of new anthracycline drugs. Antibiot Chemother 25: I2 20. 1978
Zee-Cheng RK, Cheng CC. Antineoplastic agents. Structure-activity relationship study of bis (substituted aminoalkylamino) anthraquinones. J Med Chem 1978;21(3):291–294
Delgado, J. L., Hsieh, C. M., Chan, N. L., Hiasa, H. (2018). Topoisomerases as anticancer targets. Biochemical Journal, 475(2), 373-398.
Kayaalp O. Rasyonel Tedavi Yönünden Tıbbi Farmakoloji (12.Baskı), 1.cilt, Pelikan Yayıncılık, Ankara, 2009: 337-340, 1207-1208
Skok, Z., Zidar, N., Kikelj, D., Ilaš, J. (2019). Dual inhibitors of human DNA topoisomerase II and other cancer-related targets. Journal of medicinal chemistry.https://doi.org/10.1021/acs.jmedchem.9b00726
